PDS Biotechnology is no longer the late-stage HPV immunotherapy story the equity spent two years selling. In mid-August the Princeton company told shareholders it is stopping internal funding of the late-stage HPV trial and shifting remaining capital onto PDS0301. That candidate is a tumor-targeted interleukin-twelve immunocytokine. That is a capital decision dressed as a scientific one. Management could not finance a registrational program while cash fell to $6 million at mid-year and the auditor language in the June quarterly already recorded substantial doubt about going concern. The equity now prices a survival recapitalization around an earlier-stage colorectal signal, not a near-term biologics license.
The financing that arrived after the print is the other half of the same story. On September 14 Nant Capital led an initial private placement of $11 million at roughly twenty-eight cents a unit, issued tens of millions of new shares and pre-funded warrants, and put Patrick Soon-Shiong and a NantBio finance executive on the board. A second tranche of $11 million is contingent on submitting a registrational protocol for PDS0301 designed with Nant. NantWorks also received a one-year exclusive right to negotiate a license to the abandoned HPV program. The structure buys time and a famous sponsor; it does not restore a clean balance sheet. Mid-year equity was already negative, a $6 million Yorkville note still sat on the books, and Nasdaq had already opened a bid-price cure window after the stock spent thirty sessions under a dollar.
What the next year actually tests is narrower than the pipeline slide. Either the Nant relationship funds a randomized Phase 2b in microsatellite-stable colorectal cancer with liver metastases and keeps the listing intact, or the company remains a going-concern microcap whose remaining asset is a small National Cancer Institute single-arm dataset plus an option someone else may or may not take on PDS0101. The market is not paying for peak sales. It is paying a thin call on whether a celebrity-backed recap can carry an immunocytokine through the next protocol and the next raise.